TAK-019
TAK-019-1501
Phase 2 mab completed
Quick answer
TAK-019 for Prevention of Infection Disease Caused by Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) is a Phase 2 program (mab) at Takeda Pharmaceuticals International AG with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Takeda Pharmaceuticals International AG
- Indication
- Prevention of Infection Disease Caused by Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2)
- Phase
- Phase 2
- Modality
- mab
- Status
- completed